Table 1 Characteristics of eligible studies in this meta-analysis
ID | Year | Country | Sample size (high/low) | Cancer type | Method | Outcomes | HR availability | Follow-up months (mouth) | NOS Score |
|---|---|---|---|---|---|---|---|---|---|
Zhu 2020 [35] | 2020 | China | 60 (30/30) | Osteosarcoma | qRT-PCR | OS, PFS, CP | K-M curve | 60 | 5 |
Lv 2019 [27] | 2019 | China | 114 (58/56) | Cervical cancer | qRT-PCR | OS, PFS, CP | K-M curve | 60 | 6 |
Wan 2016 [18] | 2016 | China | 58 (27/31) | Lung cancer | qRT-PCR | OS, CP | K-M curve | 60 | 6 |
Wang 2020 [28] | 2020 | China | 67 (37/30) | Pancreatic ductal adenocarcinoma | qRT-PCR | OS, CP | K-M curve | 60 | 6 |
Wu 2019 [26] | 2019 | China | 73 (37/36) | Colorectal cancer | qRT-PCR | OS, CP | K-M curve | 60 | 6 |
Wu 2020 [23] | 2020 | China | 106 (70/36) | Osteosarcoma | qRT-PCR | OS, PFS, CP | K-M curve | 60 | 6 |
Zhang 2020 [34] | 2020 | China | 106 (53/53) | Bladder cancer | qRT-PCR | OS, PFS, CP | K-M curve | 150 | 7 |
Xu 2018 [33] | 2018 | China | 72 (36/36) | Gastric cancer | qRT-PCR | OS, CP | K-M curve | 100 | 6 |
Shi 2018 [25] | 2018 | China | 60 (31/29) | Lung cancer | qRT-PCR | CP | K-M curve | – | 6 |
Kong 2019 [24] | 2019 | China | 42 (18/24) | Ovarian cancer | qRT-PCR | CP | K-M curve | – | 6 |